1. Home
  2. EVT vs ZYME Comparison

EVT vs ZYME Comparison

Compare EVT & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eaton Vance Tax Advantaged Dividend Income Fund of Beneficial Interest

EVT

Eaton Vance Tax Advantaged Dividend Income Fund of Beneficial Interest

HOLD

Current Price

$24.95

Market Cap

2.0B

Sector

Finance

ML Signal

HOLD

Logo Zymeworks Inc.

ZYME

Zymeworks Inc.

HOLD

Current Price

$23.60

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EVT
ZYME
Founded
N/A
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.8B
IPO Year
2003
2022

Fundamental Metrics

Financial Performance
Metric
EVT
ZYME
Price
$24.95
$23.60
Analyst Decision
Strong Buy
Analyst Count
0
11
Target Price
N/A
$38.90
AVG Volume (30 Days)
95.7K
651.1K
Earning Date
01-01-0001
05-18-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
33.33
EPS
N/A
N/A
Revenue
N/A
$105,965,000.00
Revenue This Year
N/A
$162.82
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
38.87
52 Week Low
$20.56
$9.03
52 Week High
$26.65
$28.49

Technical Indicators

Market Signals
Indicator
EVT
ZYME
Relative Strength Index (RSI) 32.10 49.02
Support Level $24.07 $22.23
Resistance Level $25.92 $23.66
Average True Range (ATR) 0.36 1.42
MACD -0.15 -0.06
Stochastic Oscillator 18.65 23.34

Price Performance

Historical Comparison
EVT
ZYME

About EVT Eaton Vance Tax Advantaged Dividend Income Fund of Beneficial Interest

EATON VANCE TAX ADVANTAGED DIVIDEND INCOME FUND is a diversified, closed-end management investment company. Its objective is to provide a high level of after-tax total return consisting mainly of tax-advantaged dividend income and capital appreciation. The fund pursues its objective by investing in dividend-paying common and preferred stocks. Its portfolio of investments consists of electric utilities, energy equipment and services, food products, health care providers and services, internet software and services, and other areas.

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Share on Social Networks: